Compounds > 2,4,5-tribromoimidazole
Page last updated: 2024-12-05

2,4,5-tribromoimidazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,4,5-tribromoimidazole: induces poisoning typical of uncouplers of oxidative phosphorylation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16253
CHEMBL ID363992
SCHEMBL ID69879
MeSH IDM0131172

Synonyms (40)

Synonym
AC-7522
AKOS015835021
1h-imidazole, 2,4,5-tribromo-
imidazole, 2,4,5-tribromo-
2,4,5-tribromoimidazole
einecs 217-997-5
ai3-62059
nsc 514965
brn 0115314
2,4,5-tribromo-1h-imidazole
AC-907/25014002
imidazole,4,5-tribromo-
2034-22-2
1h-imidazole,4,5-tribromo-
nsc514965
2,5-tribromoimidazole
nsc-514965
2,4,5-tribromoimidazole, 97%
T2266
CHEMBL363992
A4426
50v0252s9a ,
unii-50v0252s9a
5-23-04-00465 (beilstein handbook reference)
FT-0609785
AM20090155
CL2210
SCHEMBL69879
2,4,5-tribromo-imidazole
2,4,5-tribromo imidazole
tribromoimidazole
W-107629
2,4,5-tribromo-1h-imidazole #
DTXSID2022173
mfcd00005184
CS-W001961
Q27893870
AS-15002
EN300-140762
Z1269217056

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Dosing of TCI and TBI to rats resulted within 24-48 hr in neuronal necrosis within the CNS involving the vestibular nucleus, red nucleus, and outer parietal neocortex and ataxia of the hindlimbs."( The relationship between uncoupling of oxidative phosphorylation and neuronal necrosis within the CNS in rats dosed with trihalogenated imidazoles.
Bird, I; Brown, AW; Ray, DE; Verschoyle, RD, 1987)		0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID248488Concentration required to inhibit stationary human HFF cell line growth was determined by microscopy examination2004Journal of medicinal chemistry, Nov-04, Volume: 47, Issue:23
Synthesis and antiviral evaluation of polyhalogenated imidazole nucleosides: dimensional analogues of 2,5,6-trichloro-1-(beta-D-ribofuranosyl)benzimidazole.
AID248192Concentration required to inhibit plaque formation in human cytomegalovirus cultures was determined2004Journal of medicinal chemistry, Nov-04, Volume: 47, Issue:23
Synthesis and antiviral evaluation of polyhalogenated imidazole nucleosides: dimensional analogues of 2,5,6-trichloro-1-(beta-D-ribofuranosyl)benzimidazole.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (40.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.34 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.14 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
uracil
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder		210pyrimidine nucleobase;
pyrimidone		allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
azomycin
azomycin: RN given refers to parent cpd with specified locant; structure		1.9710C-nitro compound;
imidazoles		antitubercular agent
4-methylimidazole
4-methylimidazole: RN given refers to parent cpd. 4-methylimidazole : Imidazole substituted at position 4 by a methyl group.		1.9710imidazolescarcinogenic agent;
reaction intermediate
4-nitroimidazole
5-nitroimidazole : A C-nitro compound that is imidazole bearing a nitro substituent at position 5.		1.9710C-nitro compound;
imidazoles
terbacil
terbacil: RN given refers to parent cpd; structure		710organohalogen compound;
pyrimidines
2,5,6-trichloro-1-(ribofuranosyl)benzimidazole
[no description available]		2.0210
ganciclovir
[no description available]		2.02102-aminopurines;
oxopurine		antiinfective agent;
antiviral drug
ConditionIndicatedRelationship StrengthStudiesTrials
Cytomegalovirus
A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.		02.0210
Ataxia
Impairment of the ability to perform smoothly coordinated voluntary movements. This condition may affect the limbs, trunk, eyes, pharynx, larynx, and other structures. Ataxia may result from impaired sensory or motor function. Sensory ataxia may result from posterior column injury or PERIPHERAL NERVE DISEASES. Motor ataxia may be associated with CEREBELLAR DISEASES; CEREBRAL CORTEX diseases; THALAMIC DISEASES; BASAL GANGLIA DISEASES; injury to the RED NUCLEUS; and other conditions.		01.9710
Necrosis
The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.		01.9710